Monitoring the use of nifurtimox-eflornithine combination therapy (NECT) in the treatment of second stage gambiense human African trypanosomiasis

References

• SimarroPPCecchiGPaoneMThe Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseasesInt J Health Geogr201095721040555
   PubMed Web of Science ®Google Scholar
• SimarroPPJanninJCattandPEliminating human African try-panosomiasis: where do we stand and what comes next?PLoS Med20085e5518303943
   PubMed Web of Science ®Google Scholar
• BarrettMPBoykinDWBrunRTidwellRRHuman African trypanosomiasis: pharmacological re-engagement with a neglected diseaseBr J Pharmacol20071521155117117618313
   PubMed Web of Science ®Google Scholar
• BurriCBrunRHuman African trypanosomiasisCookGCZumlaAManson’s Tropical Diseases 21st edLondon, UKElsevier Science limited200313031323
   Google Scholar
• BurriCChemotherapy against human African trypanosomiasis: Is there a road of success ?Parasitology20101371987199420961469
   PubMed Web of Science ®Google Scholar
• World Health OrganizationWHO model list of essential medicines, 16th list March 2009Geneva, SwitzerlandWHO2009 Available from: http://www.who.int/medicines/publications/essentialmedicines/en/index.htmlAccessed January 30, 2012
   Google Scholar
• PriottoGKasparianSNgouamaDNifurtimox-Eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in CongoClin Infect Dis2007451435144217990225
   PubMed Web of Science ®Google Scholar
• PriottoGKasparianSMutomboWNifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trialLancet2009374566419559476
   PubMed Web of Science ®Google Scholar
• Who.int [homepage on the Internet]World Health Organization: Human African trypanosomiasis. Symptoms, diagnosis and treatment Available from: http://www.who.int/trypanosomiasis_african/diagnosis/en/index.htmlAccessed April 30, 2012
   Google Scholar
• SimarroPPFrancoJRDiarraAPostigoJAJanninJUpdate on field use of the available drugs for the chemotherapy of human African trypanosomiasisParasitology2012139784284622309684
   PubMed Web of Science ®Google Scholar
• World Health OrganizationSafety of Medicines – A Guide to Detecting and Reporting Adverse Drug Reactions – Why Health Professionals Need to Take ActionWHO/EDM/QSM/2002Geneva, SwitzerlandWHO2002
   Google Scholar
• Evs.nci.nih.gov [homepage on the Internet]. US Department of Health and human services, National Institutes of Health, National Cancer InstituteCommon Terminology Criteria for Adverse Events (CTCAE). Version 4.01 Available from http://evs.nci.nih.gov/ftp1/CTCAE/About.htmlAccessed January 30, 2012
   Google Scholar
• World Health OrganizationEpidemiology and control of African trypanosomiasis. Report of a WHO Expert CommitteeTechnical Report Series 739Geneva, SwitzerlandWHO1986
   Google Scholar
• BlumJNkunkuSBurriCClinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasisTrop Med Int Health20016539040011348533
   PubMed Web of Science ®Google Scholar
• AltchehJBiancardiMLapenaABalleringGFreilijHCongenital Chagas disease: experience in the Hospital de Niños, Ricardo Gutiérrez, Buenos Aires, ArgentinaRev Soc Bras Med Trop200538Suppl 24145 Spanish16482812
   PubMed Web of Science ®Google Scholar
• NgampoSSuivi post-thérapeutique des malades trypanosomés à T. b. gambiense: problèmes et perspectives. [post-therapeutical follow-up of T.b. gambiense: problems and perspectives]Antwerp, BelgiumInstituut voor Tropische Geneeskunde1992 French
   Google Scholar
• RobaysJLefortALutumbaPDrug toxicity and cost as barriers to community participation in HAT control in the Democratic Republic of CongoTrop Med Int Health20071229029817300638
   PubMed Web of Science ®Google Scholar
• MiézanTWDjéNNDouaFBoaFHuman African trypanosomiasis in Ivory Coast: biological characteristics after treatment. 812 cases treated in the Daloa focus (Ivory Coast)Bull Soc Pathol Exot Fil200295362365 French
   Web of Science ®Google Scholar
• World Health OrganizationRecommendations of the informal consultation on issues for clinical product development for human African trypanosomiasisGeneva, SwitzerlandWHO/CDS/NTD/IDM2007
   Google Scholar
• PriottoGPinogesLBadi FursaISafety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort studyBMJ200829336764670570818321960
   PubMed Web of Science ®Google Scholar
• ChecchiFPiolaPAyikoruHThomasFLegrosDPriottoGNifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case seriesPloS Negl Trop Dis20071e6418060083
   PubMed Web of Science ®Google Scholar
• PriottoGFoggCBalasegaramMThree drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a random-ized clinical trial in UgandaPLoS Clin Trials20061e3917160135
   PubMedGoogle Scholar
• PriottoGEflornithine for first line-treatment of trypanosomiasis: assessment of safety and effectiveness. Ibba, South SudanParis, FranceEpicentre2003
   Google Scholar
• PepinJKhondeNMaisoFShort course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trialBull World Health Organ2000781284129511143188
   PubMed Web of Science ®Google Scholar
• Valverde MordtOSchmidCKandeVIn-hospital safety of NECT use to treat 2nd stage T. b. gambiense in African children, pregnant and breast-feeding womenEuropean Congress of Tropical Medicine and International HealthBarcelona, SpainOctober 5, 2011
   Google Scholar
• JacksonYAlirolEGetazLWolffHCombescureCChappuisFTolerance and safety of nifurtimox in patients with chronic chagas diseaseClin Infect Dis201051e69e7520932171
   PubMed Web of Science ®Google Scholar